Table 2.
Baseline characteristics of COVID-PR participants treated with sotrovimab (N = 39)
| Characteristic | N | % |
|---|---|---|
| Age, years | ||
| 21–25 | 3 | 7.7 |
| 26–30 | 11 | 28.2 |
| 31–35 | 13 | 33.3 |
| 36–40 | 12 | 30.8 |
| Ethnicity | ||
| White/Caucasian | 33 | 84.6 |
| Black/African American | 1 | 2.6 |
| Middle Eastern/North African | 1 | 2.6 |
| Missing data | 4 | 10.3 |
| Tobacco use | ||
| None | 25 | 64.1 |
| Yes, before this pregnancy | 6 | 15.4 |
| Yes, before and during this pregnancy | 1 | 2.6 |
| Missing data | 7 | 17.9 |
| Alcohol use during pregnancy | ||
| Never | 29 | 74.4 |
| Once per month | 2 | 5.1 |
| Once per week | 1 | 2.6 |
| Missing data | 7 | 17.9 |
| Gestational timing of treatment | ||
| First trimester | 14 | 35.9 |
| Second trimester | 17 | 43.6 |
| Third trimester | 8 | 20.5 |
| Vitamin use during pregnancy | ||
| Daily | 24 | 61.5 |
| 4–6 times/week | 8 | 20.5 |
| Missing data | 7 | 17.9 |
| Pre-pregnancy body mass index | ||
| 18.5–25.9 | 15 | 38.5 |
| 26.0–30.0 | 8 | 20.5 |
| > 30.1 | 11 | 28.2 |
| Missing data | 5 | 12.8 |
| Self-reported pre-pregnancy health | ||
| Excellent | 14 | 35.9 |
| Very good | 13 | 33.3 |
| Good | 5 | 12.8 |
| Fair | 1 | 2.6 |
| Missing data | 6 | 15.4 |
| Existing medical conditions at onset of pregnancy | ||
| None | 14 | 35.9 |
| At least one condition | 14 | 35.9 |
| Asthma | 6 | 15.4 |
| Crohn’s disease | 1 | 2.6 |
| Hyperthyroidism | 1 | 2.6 |
| Hypothyroidism | 2 | 5.1 |
| Low blood pressure | 1 | 2.6 |
| Polycystic ovary syndrome | 6 | 15.4 |
| Other | 2 | 5.1 |
| Missing data | 11 | 28.2 |
COVID-19 coronavirus disease 2019, COVID-PR COVID-19 International Drug Pregnancy Registry